Literature DB >> 22571276

Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia.

R Zakharyan1, M Petrek, A Arakelyan, F Mrazek, S Atshemyan, A Boyajyan.   

Abstract

Schizophrenia is a severe psychiatric disease with inflammatory component. Several studies indicated the increased blood levels of proinflammatory interleukin-6 cytokine in schizophrenia. However, only limited studies explored the relationship between excess production and genetic variations of this cytokine in schizophrenia, and the results were controversial. Here, we investigated possible association of the interleukin-6 gene (IL6) rs1800795 (-174G/C) polymorphism with schizophrenia and relationship between this polymorphism and interleukin-6 protein (IL-6) blood levels. This polymorphism was found by other researchers to associate with different transcription rates and different plasma levels of IL-6. A total of 208 unrelated Armenians were genotyped by polymerase chain reaction with sequence-specific primers, and IL-6 levels were assessed by enzyme-linked immunosorbent assay. The IL6 rs1800795 alleles and genotypes in both groups were in Hardy-Weinberg (H-W) equilibrium. We found that rs1800795*C allele [38% vs 24%, P = 0.002, odds ratio (OR) = 1.95, 95% confidence interval (CI): 1.18-2.14] and its carriers (62% vs 42%, P = 0.003, OR = 2.28, 95% CI: 1.13-1.94) were more frequent in patients than in controls. IL-6 in patients was 1.5-fold higher than in controls (mean ± SD: 6.41 ± 2.47 pg/ml vs 4.15 ± 1.42 pg/ml, P = 1.9E-19). In both groups, higher IL-6 in rs1800795 GG compared to rs1800795*C allele carriers was observed (GG vs GC + CC, patients: 7.02 ± 2.83 pg/ml vs 5.39 ± 1.2 pg/ml, P = 0.0006; controls: 5.21 ± 1.17 pg/ml vs 3.38 ± 1.03 pg/ml, P = 1.6E-15). In conclusion, we report an association of IL6 rs1800795 and higher IL-6 with schizophrenia. We also conclude that IL6 rs1800795*C allele is linked to increased IL-6 blood levels and may be a risk factor for schizophrenia development at least in Armenian population.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571276     DOI: 10.1111/j.1399-0039.2012.01886.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  20 in total

1.  Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.

Authors:  Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste
Journal:  Am J Geriatr Psychiatry       Date:  2016-10-17       Impact factor: 4.105

Review 2.  Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications.

Authors:  Monojit Debnath; Michael Berk
Journal:  Schizophr Bull       Date:  2014-04-07       Impact factor: 9.306

Review 3.  Blood-based biomarkers predicting response to antidepressants.

Authors:  Yasmin Busch; Andreas Menke
Journal:  J Neural Transm (Vienna)       Date:  2018-01-27       Impact factor: 3.575

4.  Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia.

Authors:  Borja García-Bueno; Patricia Gassó; Karina S MacDowell; Luis F Callado; Sergi Mas; Miguel Bernardo; Amalia Lafuente; J Javier Meana; Juan C Leza
Journal:  J Psychiatry Neurosci       Date:  2016-04       Impact factor: 6.186

5.  Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966.

Authors:  Brian J Miller; Karl-Heinz Herzig; Jari Jokelainen; Toni Karhu; Sirkka Keinänen-Kiukaanniemi; Marjo-Riitta Järvelin; Juha Veijola; Heimo Viinamäki; Erika Jääskeläinen; Matti Isohanni; Markku Timonen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-07       Impact factor: 5.270

6.  Urinary proteins, vitamin D and genetic polymorphisms as risk factors for febrile urinary tract infection and relation with bacteremia: a case control study.

Authors:  Willize E van der Starre; Cees van Nieuwkoop; Uginia Thomson; Marleen S M Zijderveld-Voshart; Jan Pieter R Koopman; Tanny J K van der Reijden; Jaap T van Dissel; Esther van de Vosse
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

7.  Relationship between Interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naïve schizophrenia: evidence for differential susceptibility?

Authors:  Sunil Vasu Kalmady; Ganesan Venkatasubramanian; Venkataram Shivakumar; S Gautham; Aditi Subramaniam; Dania Alphonse Jose; Arindam Maitra; Vasanthapuram Ravi; Bangalore N Gangadhar
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

Review 8.  Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?

Authors:  Alexandru Dan Grigore; Eshel Ben-Jacob; Mary C Farach-Carson
Journal:  Front Oncol       Date:  2015-03-03       Impact factor: 6.244

9.  Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation.

Authors:  Dorota Frydecka; Błażej Misiak; Edyta Pawlak-Adamska; Lidia Karabon; Anna Tomkiewicz; Paweł Sedlaczek; Andrzej Kiejna; Jan Aleksander Beszłej
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-12       Impact factor: 5.270

10.  Genetic variants in transforming growth factor-β gene (TGFB1) affect susceptibility to schizophrenia.

Authors:  Dorota Frydecka; Blazej Misiak; Jan Aleksander Beszlej; Lidia Karabon; Edyta Pawlak-Adamska; Anna Tomkiewicz; Anna Partyka; Anna Jonkisz; Andrzej Kiejna
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.